We are a purpose-driven team, passionate about developing innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders, beginning with postpartum depression (PPD). Leveraging our team’s extensive experience in neuroscience drug development, we are advancing RE104, a patented, clinical-stage drug candidate designed as a safe, fast-acting, short duration therapy for patients with underserved mental health disorders. RE104, the only 4-OH-DiPT prodrug in clinical development, will be evaluated in the RECONNECT Phase 2 clinical trial as a potential treatment for PPD that could provide rapid symptom relief and durable efficacy.
In addition to advancing our lead candidate, RE104, we are developing our RE200 series of drug discovery candidates for application in more chronic treatment paradigms and indications. These therapies are structurally similar to classic psychedelics and designed to have selective potency at the target serotonin 2A receptor (5HT2AR) and are devoid of off-target 5HT2B receptor agonism.